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(∼108 TCID50/ml) but not in Vero cells (105—6 TCID50/ml)
which is the most common cell line for manufacturing
human vaccines. After several passages and plaque puriﬁca-
tions, two Vero-adapted high growth inﬂuenza H5N1 vaccine
viruses (Vero-15 and Vero-16) have been selected and could
reach high virus titer (108 TCID50/ml) in Vero cells in T
ﬂasks. After tested with NIBRG-14 standard antiserum pro-
vided by the NIBSC, antigenicity of the Vero-15 and Vero-16
viruses remain similar to the NIBRG-14 virus. In addition,
the Vero-15 and Vero-16 viruses do not have any nucleotide
difference in HA and NA gene segments compared with the
NIBRG-14. For process development, Vero cells were fur-
ture cultured on cytodex 1 microcarriers in spinner ﬂasks.
Vero cells growed to 3× 106 cells/ml with a seeding density
of 4.4× 105 cells/ml in 5 g/L microcarriers and peak virus
titers reached 109 TCID50/ml. In conclusion, the Vero-15 and
Vero-16 viruses are suitable for production of inﬂuenza H5N1
vaccines in Vero cells. Their other six internal gene segments
could also be used to generate vaccine seed viruses of other
inﬂuenza subtypes for production in Vero cells.
doi:10.1016/j.ijid.2008.05.687
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Streptococcus pneumoniae (pneumococcus) is an impor-
tant pathogen that causes pneumonia, meningitis and otitis
media. Invasive diseases usually follow colonization of the
respiratory tract and may be favored by factors that cause
immunosupression. Several pneumococcal proteins actively
participate of these events playing different roles such as
facilitating bacterial adhesion to epithelial cells or evasion
from the immune system. Pneumococcal Surface protein
C (PspC) is a virulence factor that has been implicated
both in colonization and in invasive phases of pneumococcal
diseases. Antigen delivery systems based on live recombi-
nant lactic acid bacteria represents a promising strategy
for mucosal vaccination, since they are able to elicit both
systemic and mucosal immune responses. In the present
work, we have evaluated the immune response and the
protective activity of nasal vaccines composed of recom-
binant PspC (rPspC) or Lactobacillus casei expressing PspC
(L.c.PspC). Nasal immunization of mice with both formula-
tions did not elicit the production of anti-PspC IgG or IgA.
On the other hand, ELISPOT and cytokine ELISA analysis of
cultures obtained from mice 13 h after intranasal challenge
with a virulent pneumococcal strain, showed an increase
in IFN- secretion in lung cells from mice immunized with
L.c.PspC and to a lesser extent, rPspC. This cytokine was also
produced by spleen cells from mice immunized with both
formulations. Production of IL-17 by lung cells was observed
in the group immunized with rPspC whereas immuniza-
tion with L.c.PspC induced the production of this cytokine
only by spleen cells. IL-17 has already been implicated in
the protection against colonization conferred by a cellular
pneumococcal vaccine. Nevertheless, the induction of this
cytokine or IFN- by our vaccines did not confer protection
against an invasive challenge with pneumococci. Further
studies will be necessary for the evaluation of protection
against nasal colonization.
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DNA Vaccine Construct in the Presence of EV71 IRES
Elicited Higher Neutralizing Antibody Titre
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Since 1997, large epidemics of EV71 infection have been
reported in East and Southeast Asia. The virus has caused
numbers of outbreak and infection associated with fatal neu-
rological complications, however no vaccine nor antiviral
against EV71 are available. In our study, we have devel-
oped DNA-based vaccines against EV71. The vaccines consist
of structural protein VP1 of human enterovirus 71 (EV71)
as fusion proteins with enhanced green ﬂuorescent protein
(EGFP), with and without the presence of internal ribosome
entry site (IRES) at the 5′-end; IRESVP1/EGFP and VP1/EGFP.
Expressions of both constructs were evaluated in vitro using
Vero and SK-N-MC cells, and later in vivo in murine model.
Evaluation of in vitro expression showed that the VP1 gene
expressed by 5′UTR-VP1/EGFP is higher in comparison to
construct without IRES; VP1/EGFP, in both Vero and SK-N-MC
cells. The ability of the constructed DNA vaccines in elicit-
ing immune responses were evaluated in vivo using murine
model. Themice were immunized with 2 dosages of DNA vac-
cine followed by experimental challenge. In vivo evaluation
showed that the mice group immunized with IRESVP1/EGFP
confer a higher neutralizing antibody titer in comparison to
the VP1/EGFP. Results from our study not only demonstrate
the potential of VP1-based DNA vaccine but also suggests the
feasibility of using IRES to generate better protective immu-
nity in mice against EV71 and the possibility to develop safe
vaccine against enterovirus infection.
doi:10.1016/j.ijid.2008.05.689
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Background: Since rabies virus (RV) infection is fatal
for both human and animals, the protective immunization
by vaccines is of critical importance for disease con-
trol and prevention. Several recombinant protein and live
viruses of rabies have been constructed and tested for their
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immunological effects. In this study, we have produced
the recombinant rabies glycoprotein (rGP) from recom-
binant baculovirus-infected insect cells and recombinant
adenovirus expressing rabies glycoprotein (rAdV). We also
investigated immunity induced by those protein and virus in
experimental mice.
Methods: For construction of rGP and rAdV, G gene from
ﬁeld isolate (SKRRD9901PJ) was altered to replace with the
codons preferred in insect cell and mammalian cell for its
high-level expression. In baculovirus expression system, bac-
ulovirus DNA including genes of chaperones such as heat
shock proteins was used in order to prevent aggregation
of rGP and elevate its solubility. The replication-defective
adenovirus expressing rabies glycoprotein was created by
homologous recombinant in HEK 293 cell using human aden-
ovirus serotype 5 DNA deleted the early transcribed E1 and
E3 genes. Five female ICR mice were immunized two times
in a 30-day interval with 0.4mg of insect cell lysate includ-
ing rGP given intramuscularly. Groups of ﬁve female mice
were immunized with ten-fold serially diluted rAdV (107—104
TCID50) given intramuscularly and 108—106 TCID50 titer given
orally. Mice were periodically bled under anaesthesia by
retro-orbital puncture. Virus-neutralizing antibodies (VNA)
were determined with CVS-11 virus on BHK-21 cells as FAVNT
method and commercial ELISA (Bio-Rad).
Results and conclusion: While the VNA titers by single
inoculation of rGP were low and did not continue long in
existence, titers by booster injection exceeded the 0.5 IU
by 180 days. However, these immunities were inferior to
those by commercial inactivated vaccines. All mice immu-
nized intramuscularly with low titer of rAdV developed high
VNA within 7—14 days after one inoculation. In experiment
of oral immunization of rAdV, although titer of VNA varied in
individual mice, geometric mean titers showed dose depen-
dent. VNA titers of above 2.5 IU could be elicited after oral
immunization by rAdV with titer of 106 TCID50 and those anti-
bodies were lasted by 180 days without decline of titers. As a
conclusion, rAdV induced high titers of rabies VNA compared
to rGP and was suitable as material to induce protective
immunity against rabies.
doi:10.1016/j.ijid.2008.05.690
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The Antimicrobial Resistance of Streptococcus pneumo-
nia by E-test Method
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Pneumococcus is among most common gram-positive
bacteria causing infection in human. Unfortunately resis-
tance of Pneumococcus is increasing daily like other
bacteria. Considering that no useful research regarding rate
of resistance of Pneumococcus against ceftriaxone has been
done by E-test method (at least in Isfahan province), the
above study can be a base for future studies about determi-
nation of increase or decrease in Pneumococcus resistance
rate.
Method: This cross-sectional prospective study was per-
formed in 1385 on 98 Streptococcus pneumonia samples
separated from clinical samples of patients presenting to
Al-Zahra Hospital, and then MIC (Minimal Inhibitory Con-
sentration) of antibiotics ceftriaxone and penicillin on the
organisms was determined using E-Test method. Quality con-
trol was done using Pneumococcus ATCC 49619. After editing
and entering in to computer, data were analyzed using SPSS-
13 and WHONET-5.
Results: This study was performed on 98 patients with
age range between 5 to 10 years. Among patients, 47% are
female and 53% are male. The studied samples are 55% from
throat, 20% from CSF, 16.5% from blood, 3% from pleural
ﬂuid, 3% from ear (patients with otitis), 1% (1 person) from
abscess and 1% (1 person) from wound. Separated Pneu-
mococci showed about 30% sensitivity to penicillin whereas
MIC of ceftriaxone for cases other than meningitis is about
90% sensitivity and this MIC for meningitis considering lesser
penetration of the drug in CNS, is 81.5% sensitivity.
Conclusion: Penicillin is not an effective drug for cov-
erage of Pneumococcus even in children, but considering
effectiveness of ceftriaxone, this drug alone is sufﬁcient in
cases suspicious of Pneumococcus at early presentation and
vancomycin is not needed before culture result and antibi-
ogram.
doi:10.1016/j.ijid.2008.05.691
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Despite of the gained success in diagnostics and treat-
ment, pneumococcal infection is still remaining the leading
cause if pneumonias, meningitis etc in different groups
of population, including groups with different risk factors
such as age, immunodeﬁciency, chronical somatic diseases.
On data of the previous research projects of pneumococ-
cal infections in our city, the incidence of pneumococcal
pneumonias in adults over 18 years is 36 per 100 000 of popu-
lation. The aim of our research was to study epidemiology of
the pneumococcal pneumonias in patients with low immune
status and without any clinical immune disturbances.
Methods: we studied 140 isolates of S.pneumoniae gained
from patients with pneumococcal pneumonias at the age of
18—40 years, without any others somatic or immune com-
plications (group 1), and 65 isolates gained from patients of
18—72 years with hematology diseases (myeloma, leucosis,
etc); antimicrobial resistance was studied on NCCLS stan-
dards with disk-diffusion and microdiltion methods; there
were performed serotyping and PFGE.
Results: there were revealed only (0/6, 15%) of strains
resistant to penicillin (group 1 vs.group 2); 34,2%/56, 9%
strains resistant to tetracycline, 15, 7%/24, 6% strains resis-
tant to erythromycin, 15%/18,4% resistant to levoﬂoxacin,
55, 7%/40, 3% resistant to co-trimoxazole and 11,4%/12, 3%
